Overview
Bionano Q3 2025 revenue grows 21% yr/yr, beating analyst expectations
Company's gross margin improves to 46% from (139)% in Q3 2024
Operating expenses reduced by 66% to $11.9 mln
Outlook
Bionano expects Q4 2025 revenue between $7.5 mln and $7.9 mln
Company maintains full-year 2025 revenue guidance of $26 mln to $30 mln
Bionano anticipates over 25 new OGM system installations in 2025
Result Drivers
CONSUMABLES AND SOFTWARE - Increased utilization among routine users drove revenue growth, per CEO Erik Holmlin
EXPANSION IN JAPAN - Growing utilization of optical genome mapping in Japan supports revenue growth
OGM SYSTEM INSTALLATIONS - Installation of new OGM systems contributed to revenue increase
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $7.40 mln | $6.87 mln (3 Analysts) |
Q3 Gross Margin | 46.00% | ||
Q3 Adjusted Operating Expenses | $9.70 mln | ||
Q3 Operating Expenses | $11.90 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Bionano Genomics Inc is $9.50, about 83.2% above its November 12 closing price of $1.60
Press Release: ID:nGNX7TFQMF
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)